FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311448439> ?p ?o ?g. }

• W4311448439 endingPage "2219" @default.
• W4311448439 startingPage "2211" @default.
• W4311448439 abstract "Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). Beremagene geperpavec (B-VEC) is a topical investigational herpes simplex virus type 1 (HSV-1)-based gene therapy designed to restore C7 protein by delivering COL7A1.We conducted a phase 3, double-blind, intrapatient randomized, placebo-controlled trial involving patients 6 months of age or older with genetically confirmed dystrophic epidermolysis bullosa. For each patient, a primary wound pair was selected, with the wounds matched according to size, region, and appearance. The wounds within each pair were randomly assigned in a 1:1 ratio to receive weekly application of either B-VEC or placebo for 26 weeks. The primary end point was complete wound healing of treated as compared with untreated wounds at 6 months. Secondary end points included complete wound healing at 3 months and the change from baseline to weeks 22, 24, and 26 in pain severity during changes in wound dressing, assessed with the use of a visual analogue scale (scores range from 0 to 10, with higher scores indicating greater pain).Primary wound pairs were exposed to B-VEC and placebo in 31 patients. At 6 months, complete wound healing occurred in 67% of the wounds exposed to B-VEC as compared with 22% of those exposed to placebo (difference, 46 percentage points; 95% confidence interval [CI], 24 to 68; P = 0.002). Complete wound healing at 3 months occurred in 71% of the wounds exposed to B-VEC as compared with 20% of those exposed to placebo (difference, 51 percentage points; 95% CI, 29 to 73; P<0.001). The mean change from baseline to week 22 in pain severity during wound-dressing changes was -0.88 with B-VEC and -0.71 with placebo (adjusted least-squares mean difference, -0.61; 95% CI, -1.10 to -0.13); similar mean changes were observed at weeks 24 and 26. Adverse events with B-VEC and placebo included pruritus and chills.Complete wound healing at 3 and 6 months in patients with dystrophic epidermolysis bullosa was more likely with topical administration of B-VEC than with placebo. Pruritus and mild systemic side effects were observed in patients treated with B-VEC. Longer and larger trials are warranted to determine the durability and side effects of B-VEC for this disease. (Funded by Krystal Biotech; GEM-3 ClinicalTrials.gov number, NCT04491604.)." @default.
• W4311448439 created "2022-12-26" @default.
• W4311448439 creator A5002087554 @default.
• W4311448439 creator A5004908037 @default.
• W4311448439 creator A5016220008 @default.
• W4311448439 creator A5021290428 @default.
• W4311448439 creator A5025221860 @default.
• W4311448439 creator A5031306306 @default.
• W4311448439 creator A5038951205 @default.
• W4311448439 creator A5041562335 @default.
• W4311448439 creator A5047477459 @default.
• W4311448439 creator A5054109541 @default.
• W4311448439 creator A5054891354 @default.
• W4311448439 creator A5055624947 @default.
• W4311448439 creator A5056156481 @default.
• W4311448439 creator A5062874736 @default.
• W4311448439 creator A5064047831 @default.
• W4311448439 creator A5065754086 @default.
• W4311448439 creator A5080767253 @default.
• W4311448439 date "2022-12-15" @default.
• W4311448439 modified "2023-10-18" @default.
• W4311448439 title "Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa" @default.
• W4311448439 cites W1969011049 @default.
• W4311448439 cites W2063132616 @default.
• W4311448439 cites W2098214526 @default.
• W4311448439 cites W2125072799 @default.
• W4311448439 cites W2129457098 @default.
• W4311448439 cites W2478595009 @default.
• W4311448439 cites W2546735337 @default.
• W4311448439 cites W2942860966 @default.
• W4311448439 cites W2948829110 @default.
• W4311448439 cites W2978135166 @default.
• W4311448439 cites W2986454132 @default.
• W4311448439 cites W2998937058 @default.
• W4311448439 cites W2999858469 @default.
• W4311448439 cites W3000219265 @default.
• W4311448439 cites W3005172635 @default.
• W4311448439 cites W3083652898 @default.
• W4311448439 cites W3162445048 @default.
• W4311448439 cites W4211071051 @default.
• W4311448439 cites W4214606122 @default.
• W4311448439 cites W4220939921 @default.
• W4311448439 cites W4300187280 @default.
• W4311448439 doi "https://doi.org/10.1056/nejmoa2206663" @default.
• W4311448439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36516090" @default.
• W4311448439 hasPublicationYear "2022" @default.
• W4311448439 type Work @default.
• W4311448439 citedByCount "19" @default.
• W4311448439 countsByYear W43114484392022 @default.
• W4311448439 countsByYear W43114484392023 @default.
• W4311448439 crossrefType "journal-article" @default.
• W4311448439 hasAuthorship W4311448439A5002087554 @default.
• W4311448439 hasAuthorship W4311448439A5004908037 @default.
• W4311448439 hasAuthorship W4311448439A5016220008 @default.
• W4311448439 hasAuthorship W4311448439A5021290428 @default.
• W4311448439 hasAuthorship W4311448439A5025221860 @default.
• W4311448439 hasAuthorship W4311448439A5031306306 @default.
• W4311448439 hasAuthorship W4311448439A5038951205 @default.
• W4311448439 hasAuthorship W4311448439A5041562335 @default.
• W4311448439 hasAuthorship W4311448439A5047477459 @default.
• W4311448439 hasAuthorship W4311448439A5054109541 @default.
• W4311448439 hasAuthorship W4311448439A5054891354 @default.
• W4311448439 hasAuthorship W4311448439A5055624947 @default.
• W4311448439 hasAuthorship W4311448439A5056156481 @default.
• W4311448439 hasAuthorship W4311448439A5062874736 @default.
• W4311448439 hasAuthorship W4311448439A5064047831 @default.
• W4311448439 hasAuthorship W4311448439A5065754086 @default.
• W4311448439 hasAuthorship W4311448439A5080767253 @default.
• W4311448439 hasBestOaLocation W43114484391 @default.
• W4311448439 hasConcept C126322002 @default.
• W4311448439 hasConcept C141071460 @default.
• W4311448439 hasConcept C142724271 @default.
• W4311448439 hasConcept C16005928 @default.
• W4311448439 hasConcept C168563851 @default.
• W4311448439 hasConcept C203092338 @default.
• W4311448439 hasConcept C204787440 @default.
• W4311448439 hasConcept C27081682 @default.
• W4311448439 hasConcept C2778405274 @default.
• W4311448439 hasConcept C2780269544 @default.
• W4311448439 hasConcept C2781207856 @default.
• W4311448439 hasConcept C44249647 @default.
• W4311448439 hasConcept C71924100 @default.
• W4311448439 hasConcept C90924648 @default.
• W4311448439 hasConceptScore W4311448439C126322002 @default.
• W4311448439 hasConceptScore W4311448439C141071460 @default.
• W4311448439 hasConceptScore W4311448439C142724271 @default.
• W4311448439 hasConceptScore W4311448439C16005928 @default.
• W4311448439 hasConceptScore W4311448439C168563851 @default.
• W4311448439 hasConceptScore W4311448439C203092338 @default.
• W4311448439 hasConceptScore W4311448439C204787440 @default.
• W4311448439 hasConceptScore W4311448439C27081682 @default.
• W4311448439 hasConceptScore W4311448439C2778405274 @default.
• W4311448439 hasConceptScore W4311448439C2780269544 @default.
• W4311448439 hasConceptScore W4311448439C2781207856 @default.
• W4311448439 hasConceptScore W4311448439C44249647 @default.
• W4311448439 hasConceptScore W4311448439C71924100 @default.
• W4311448439 hasConceptScore W4311448439C90924648 @default.
• W4311448439 hasIssue "24" @default.

• next